Baricitinib, specifically, is an orally administered inhibitor of JAK1 and JAK2 that blocks the intracellular signaling pathways of cytokines, which are known to be elevated in severe COVID-19, including IL-2, IL-6, interferon-γ and granulocyte-macrophage colony-stimulating factor. This evidence concerns the gene CSF2 and COVID-19.